New drug may slow progression of ALS in small group of patients: Study
Huy MachBucelli, left, and Miller co-lead WashU Medicine's ALS Center, where ongoing clinical trials continue to investigate tofersen for ALS, including its potential to prevent or delay disease onset people who have the genetic variants but have not yet shown symptoms.
Source: ABC News
